Meta-analysis of 19 comparisons showed that in blood, as in CSF, the level of tau-p181 in control subjects is about half that in AD patients (effect size = 0.556, p <0.0001). Loading data... How to ...

SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may ...

UCB’s bepranemab slowed the accumulation of tau in the brain but did not slow disease progression in its first phase II test in Alzheimer disease (AD), UCB reported. The mixed results are a blow ...

or early Alzheimer’s disease (AD), in a phase 2 trial. “We saw encouraging preliminary effects on cognition and white matter integrity for insulin and on CSF [cerebrospinal fluid] total tau ...

Eisai has tackled AD drug discovery for four decades, resulting in a symptomatic breakthrough treatment in the 1980s and the continued development of anti-amyloid and anti-tau antibodies today.

The test is designed to detect and measure disease pathology to enable the diagnosis of AD at its earliest, most treatable stages. Unlike first-generation tests that measure biomarkers indicative of ...